<DOC>
	<DOCNO>NCT02134301</DOCNO>
	<brief_summary>The purpose Phase 1 trial evaluate PK , safety tolerability oritavancin patient &lt; 18 year old confirm suspected bacterial infection .</brief_summary>
	<brief_title>Open-Label , Dose-Finding , Pharmacokinetics , Safety Tolerability Study Oritavancin Pediatric Patients With Suspected Confirmed Bacterial Infections</brief_title>
	<detailed_description>This Phase 1 , multicenter , open-label , PK , safety tolerability study oritavancin pediatric patient ( &lt; 18 year age ) suspect confirmed Gram-positive bacterial infection . Approximately 48 patient enrol 10-15 US center . This study include 5 age cohort patient enter stepwise approach start old age cohort ( 12- &lt; 18 year ) . The start dose IV oritavancin 15 mg/kg . The safety , tolerability PK data review completion cohort ensure safety determine appropriate dose next age cohort . At least 8 patient enrol cohort except birth &lt; 3 month age cohort least 16 patient enrol . Seven PK sample collect 14 day . The safety follow-up complete 60-day phone call caregiver .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Gram-Positive Bacterial Infections</mesh_term>
	<mesh_term>Oritavancin</mesh_term>
	<criteria>Males female &lt; 18 year age Neonates must least 34 week postconception age Parent legal guardian give informed consent , appropriate ; pediatric patient give verbal assent appropriate . Suspected confirmed Gram positive bacterial infection receive antibiotic therapy Intravenous access administer study drug In investigator 's opinion , patient require hospitalization least 24 hour study drug administer . Septic shock acute haemodynamic instability . History immunerelated hypersensitivity reaction glycopeptides ( vancomycin , televancin , teicoplanin ) excipients . Currently use vancomycin glycopeptides Females childbearing potential unwilling practice abstinence use least two method contraception female patient childbearing lactate positive pregnancy test result screen Males unwilling practice abstinence use acceptable method birth control entire study period Any surgical medical condition , opinion investigator , would put patient increase risk likely interfere study procedure PK study drug . Patients investigator considers unlikely adhere protocol , comply study drug administration , complete clinical study Treatment investigational medicinal product investigational device within 30 day ( 5 time halflife investigational medicine , whichever long ) enrollment duration study . Any clinically significant disease condition affect major organ system , include limited gastrointestinal , renal , hepatic , endocrinologic , bronchopulmonary , neurological , metabolic cardiovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>oritavancin</keyword>
	<keyword>pediatrics</keyword>
	<keyword>gram positive</keyword>
	<keyword>bacterial infection</keyword>
	<keyword>Confirmed</keyword>
	<keyword>Suspected</keyword>
</DOC>